Gainers

• Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session.
• SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is at $37.0 million.
• Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 19.74% to $3.7. The market value of their outstanding shares is at $1.8 million.
• CareDx (NASDAQ:CDNA) shares increased by 14.9% to $43.78. The market value of their outstanding shares is at $1.9 billion. As per the press release, Q2 earnings came out yesterday.
• Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 14.28% to $1.8. The market value of their outstanding shares is at $3.7 million.
• Zentek (NASDAQ:ZTEK) stock moved upwards by 13.89% to $0.63. The company's market cap stands at $69.8 million.

Losers

• Karyopharm Therapeutics (NASDAQ:KPTI) stock declined by 72.5% to $1.93 during Friday's regular session. The company's market cap stands at $158.8 million.
• Nuwellis (NASDAQ:NUWE) stock decreased by 63.38% to $1.63.
• Moleculin Biotech (NASDAQ:MBRX) stock declined by 62.36% to $0.38. The market value of their outstanding shares is at $5.4 million.
• Bioage Labs (NASDAQ:BIOA) stock decreased by 61.74% to $9.51. The market value of their outstanding shares is at $1.1 billion.
• Myriad Genetics (NASDAQ:MYGN) stock decreased by 46.28% to $2.88. The market value of their outstanding shares is at $507.1 million. As per the press release, Q2 earnings came out yesterday.
• GlucoTrack (NASDAQ:GCTK) stock decreased by 39.56% to $0.47. The market value of their outstanding shares is at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.